Black Diamond Therapeutics (BDTX) Investor Presentation - Slideshow

Company Overview - Black Diamond Therapeutics is developing tumor-agnostic therapies for genetically defined cancers with unmet treatment needs[6,7] - The company's MAP platform identifies oncogenic mutations across tumor types to develop spectrum-selective small molecule therapies[7] - Black Diamond is pioneering a novel scientific approach to address significant unmet medical needs in oncology[57] Pipeline and Programs - BDTX-189, an orally-available MasterKey tyrosine kinase inhibitor, is in Phase 1/2 clinical trial targeting ErbB mutations[7] - BDTX-1535, a brain-penetrant small molecule inhibitor of EGFR mutations, is advancing towards IND filing in 1H 2022[12] - BRAF and FGFR programs are in lead optimization, targeting allosteric oncogenic driver mutations with IND anticipated in 2022[12] BDTX-189 Program - BDTX-189 targets up to 30,000+ new cases across solid tumors in the US in 2020 with mutations in EGFR/HER2[21] - In NSCLC with EGFR/HER2 Exon 20 insertion mutations, BDTX-189 targets up to 7,600 cases, representing approximately 4% of ~190,000 NSCLC cases[21] - In breast cancer, BDTX-189 targets up to 8,400 cases with EGFR/HER2 Exon 20 insertions, HER2 S310 mutations, or other alloHER2 mutations, representing approximately 3% of ~280,000 breast cancer cases[21] - In solid tumors excluding breast cancer, BDTX-189 targets up to 6,000 cases with HER2 S310 mutations, representing approximately 0.5% of ~1.2 million cases[21] - In solid tumors excluding breast cancer, BDTX-189 targets up to 12,000 cases with other allo-HER2 mutations (and Solid Tumors excluding Breast Cancer and NSCLC with EGFR/HER2 Exon 20 insertion mutations), representing approximately 1% of ~1.2 million cases[21] BDTX-1535 Program - Approximately 50% of GBM tumors express oncogenic EGFR variants[38]